Pacira BioSciences financials
$25.65+1.02%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M | $429.6M | $421.0M | $337.3M | $286.6M | $276.4M |
| Gross profit | $576.7M | $530.5M | $490.3M | $467.5M | $401.3M | $312.3M | $314.3M | $250.4M | $198.7M | $166.3M |
| Gross margin | 79.4% | 75.7% | 72.6% | 70.1% | 74.1% | 72.7% | 74.7% | 74.3% | 69.3% | 60.2% |
| Operating income | $19.2M | -$73.4M | $87.7M | $60.0M | $89.9M | $46.4M | $10.5M | $15.9M | -$24.9M | -$32.0M |
| Net income | $7.0M | -$99.6M | $42.0M | $15.9M | $42.0M | $145.5M | -$11.0M | -$471.0K | -$42.6M | -$37.9M |
| Net margin | 1.0% | −14.2% | 6.2% | 2.4% | 7.8% | 33.9% | −2.6% | −0.1% | −14.9% | −13.7% |
| Diluted EPS | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 | $3.33 | $-0.27 | $-0.01 | $-1.07 | $-1.02 |
| EBITDA | $110.2M | $168.7M | $163.2M | $162.4M | $118.5M | $73.6M | $30.1M | $30.7M | -$9.9M | -$18.6M |
| Operating cash flow | $152.0M | $189.4M | $154.6M | $174.8M | $126.7M | $77.0M | $70.5M | $48.9M | $17.8M | $33.5M |
| Free cash flow | $136.7M | $178.8M | $139.5M | $144.7M | $80.8M | $39.2M | $60.4M | $34.4M | -$1.5M | $8.7M |
| Diluted shares | 45.0M | 46.2M | 52.0M | 46.5M | 45.6M | 43.7M | 41.5M | 40.9M | 39.8M | 37.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $158.5M | $276.8M | $153.3M | $104.1M | $585.6M | $100.0M |
| Short-term investments | $79.9M | $207.8M | $125.3M | $184.5M | $70.8M | $421.7M |
| Total debt | $372.2M | $585.3M | $522.4M | $689.5M | $1.05B | $462.7M |
| Total assets | $1.26B | $1.55B | $1.57B | $1.68B | $2.08B | $1.27B |
| Total liabilities | $571.8M | $775.2M | $704.3M | $906.2M | $1.34B | $654.8M |
| Shareholders' equity | $693.1M | $778.3M | $870.1M | $775.0M | $730.4M | $619.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology